{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:00:46Z","timestamp":1781708446107,"version":"3.54.5"},"reference-count":88,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K12CA001727"],"award-info":[{"award-number":["K12CA001727"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Epithelial ovarian cancer (EOC) is the most common histology of ovarian cancer defined as epithelial cancer derived from the ovaries, fallopian tubes, or primary peritoneum. It is the fifth most common cause of cancer-related death in women in the United States. Because of a lack of effective screening and non-specific symptoms, EOC is typically diagnosed at an advanced stage (FIGO stage III or IV) and approximately one third of patients have malignant ascites at initial presentation. The treatment of ovarian cancer consists of a combination of cytoreductive surgery and systemic chemotherapy. Despite the advances with new cytotoxic and targeted therapies, the five-year survival rate for all-stage EOC in the United States is 48.6%. Delivery of up-to-date guideline care and multidisciplinary team efforts are important drivers of overall survival. In this paper, we review our frontline management of EOC that relies on a multi-disciplinary approach drawing on clinical expertise and collaboration combined with community practice and cutting edge clinical and translational research. By optimizing partnerships through team medicine and clinical research, we combine our cancer center clinical expertise, community practice partnership, and clinical and translational research to understand the biology of this deadly disease, advance therapy and connect our patients with the optimal treatment that offers the best possible outcomes.<\/jats:p>","DOI":"10.3390\/jcm9092830","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T08:53:43Z","timestamp":1598950423000},"page":"2830","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Frontline Management of Epithelial Ovarian Cancer\u2014Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research"],"prefix":"10.3390","volume":"9","author":[{"given":"Edward Wenge","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Hsiao","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sariah","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Jae-Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shehayeb","sequence":"additional","affiliation":[{"name":"Department of Population Sciences, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Glaser","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Saadat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Dellinger","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest Soyoung","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wilczynski","sequence":"additional","affiliation":[{"name":"Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Rodriguez-Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"ref_1","unstructured":"Board PDQATE (2002). Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ(R)): Health Professional Version, National Cancer Institute. PDQ Cancer Information Summaries."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3322\/caac.21601","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11912-019-0816-0","article-title":"Novel Approaches to Ovarian Cancer Screening","volume":"21","author":"Nebgen","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_4","unstructured":"Howlader, N.N.A., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., and Chen, H.S. SEER Cancer Statistics Review, 1975\u20132017, National Cancer Institute. Available online: https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2014.10.023","article-title":"Ovarian cancer in the United States: Contemporary patterns of care associated with improved survival","volume":"136","author":"Cliby","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am. J. Obs. Gynecol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"ref_8","first-page":"349","article-title":"A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary","volume":"16","author":"Allen","year":"1995","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","article-title":"Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)","volume":"106","author":"Wimberger","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2007.11.0114","article-title":"Japan Multinational Trial Organization OC. PIEPOC: A new prognostic index for advanced epithelial ovarian cancer--Japan Multinational Trial Organization OC01\u201301","volume":"25","author":"Teramukai","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2006.07.004","article-title":"\u201cOptimal\u201d cytoreduction for advanced epithelial ovarian cancer: A commentary","volume":"103","author":"Eisenkop","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group Study","volume":"26","author":"Winter","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","article-title":"The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer","volume":"108","author":"Eisenhauer","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1006\/gyno.1994.1346","article-title":"Epithelial ovarian carcinoma: Principles of primary surgery","volume":"55","author":"Hoskins","year":"1994","journal-title":"Gynecologic Oncol."},{"key":"ref_19","first-page":"Cd007565","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"2011","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002164","article-title":"Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer","volume":"130","author":"Wright","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rutten, M.J., Gaarenstroom, K.N., Van Gorp, T., van Meurs, H.S., Arts, H.J., Bossuyt, P.M., Ter Brugge, H.G., Hermans, R.H., Opmeer, B.C., and Pijnenborg, J.M. (2012). Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): A multicentre randomized controlled study. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-31"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.2016.69.2962","article-title":"Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial","volume":"35","author":"Rutten","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","article-title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","volume":"28","author":"Monk","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ygyno.2020.03.034","article-title":"Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis","volume":"158","author":"Cusimano","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.suc.2020.02.009","article-title":"Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy","volume":"100","author":"Pletcher","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nadiradze, G., Horvath, P., Sautkin, Y., Archid, R., Weinreich, F.J., K\u00f6nigsrainer, A., and Reymond, M.A. (2019). Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers, 12.","DOI":"10.3390\/cancers12010034"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/bjs5.50257","article-title":"Pressurized intraperitoneal aerosol chemotherapy: A review of the introduction of a new surgical technology using the IDEAL framework","volume":"4","author":"Tate","year":"2020","journal-title":"BJS Open"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","article-title":"Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer","volume":"166","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-018-0424-x","article-title":"DNA damage repair in ovarian cancer: Unlocking the heterogeneity","volume":"11","author":"Gee","year":"2018","journal-title":"J. Ovarian Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3390\/cancers12051315","article-title":"Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas","volume":"12","author":"Milanesio","year":"2020","journal-title":"Cancers"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","article-title":"Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma","volume":"10","author":"Takaya","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group Study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_42","first-page":"517","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"89811","DOI":"10.18632\/oncotarget.20688","article-title":"A combination of circulating miRNAs for the early detection of ovarian cancer","volume":"8","author":"Yokoi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Otsuka, I., and Matsuura, T. (2020). Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding. Diagnostics, 10.","DOI":"10.3390\/diagnostics10020120"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e28932","DOI":"10.7554\/eLife.28932","article-title":"Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer","volume":"6","author":"Elias","year":"2017","journal-title":"eLife"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Guadagni, S., Clementi, M., Masedu, F., Fiorentini, G., Sarti, D., Deraco, M., Kusamura, S., Papasotiriou, I., Apostolou, P., and Aigner, K.R. (2020). A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134813"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials","volume":"322","author":"Young","year":"1990","journal-title":"N. Eng. J. Med."},{"key":"ref_49","first-page":"Cd004706","article-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","volume":"3","author":"Kitchener","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/02841860151116420","article-title":"A systematic overview of chemotherapy effects in ovarian cancer","volume":"40","author":"Hogberg","year":"2001","journal-title":"Acta Oncolog."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2016.09.015","article-title":"The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients\u2014An analysis of NRG Oncology\/Gynecologic Oncology Group trials","volume":"143","author":"Chan","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdt527","article-title":"Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016)","volume":"25","author":"Harano","year":"2014","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med.Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Eng. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): Primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.coc.0000045849.95834.6B","article-title":"Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: Case-control analysis of toxicity","volume":"27","author":"Hsu","year":"2004","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1310\/hpj5106-442","article-title":"Carboplatin and Liposomal Doxorubicin for Ovarian Cancer","volume":"51","author":"Nguyen","year":"2016","journal-title":"Hosp. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2013.07.100","article-title":"Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"131","author":"Burger","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Eng. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Eng. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","article-title":"Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group Study","volume":"25","author":"Wenzel","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: A gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Eng. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Eng. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","article-title":"NCCN Guidelines Insights: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020","volume":"18","author":"Daly","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/IGC.0b013e3182994365","article-title":"Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"23","author":"Novetsky","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_76","first-page":"1758835919897530","article-title":"How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors","volume":"12","author":"Neviere","year":"2020","journal-title":"Adv. Med. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","article-title":"A systematic review and meta-analysis of family history and risk of ovarian cancer","volume":"105","author":"Stratton","year":"1998","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103077","article-title":"A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects","volume":"52","author":"Jervis","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2013.50.9257","article-title":"American Society of Clinical Oncology Expert Statement: Collection and use of a cancer family history for oncology providers","volume":"32","author":"Lu","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3324\/haematol.2009.021626","article-title":"Constitutional mismatch repair-deficiency syndrome","volume":"95","author":"Wimmer","year":"2010","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Rafnar","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng.570","article-title":"Mutation of the RAD51C gene in a Fanconi anemia-like disorder","volume":"42","author":"Vaz","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1158\/2159-8290.CD-14-1156","article-title":"Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype","volume":"5","author":"Sawyer","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood-2003-09-3138","article-title":"Germline mutations in BRCA2: Shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia","volume":"103","author":"Wagner","year":"2004","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"15006","DOI":"10.1038\/npjgenmed.2015.6","article-title":"Precision medicine in heritable cancer: When somatic tumour testing and germline mutations meet","volume":"1","author":"Ngeow","year":"2016","journal-title":"NPJ Genomic Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"JCO1800328","DOI":"10.1200\/JCO.18.00328","article-title":"Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing","volume":"36","author":"Slavin","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/9\/2830\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:05:34Z","timestamp":1760177134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/9\/2830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":88,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["jcm9092830"],"URL":"https:\/\/doi.org\/10.3390\/jcm9092830","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}